Skin depigmentation induced by sunitinib treatment of renal cell carcinoma

Journal of the American Academy of Dermatology

Volumn 61, Issue 5, 2009, Pages 905-906

  Al Enazi, Madallah M ^a   Kadry, Razan ^a   Mitwali, Hadeel ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

MOMETASONE CREAM; PROTECTIVE AGENT; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; DEPIGMENTATION; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PRIORITY JOURNAL; RADIODIAGNOSIS; SKIN EXAMINATION;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; HYPOPIGMENTATION; INDOLES; KIDNEY NEOPLASMS; MALE; PYRROLES;

EID: 70349845716     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.12.030     Document Type: Article

References (5)

1. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
2. Heidary N., Naik H., and Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 58 (2008) 545-570
3. Bellmun J. The oncologist's view: targeted therapies in advanced renal cell carcinoma. European Urol 7 suppl (2008) 55-62
4. Hartmann J.T., and Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol 144 (2008) 1525-1526
5. Moss K.G., Toner G.C., Cherrington J.M., Mendel D.B., and Laird A.D. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307 (2003) 476-480